Is IBRX a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for ImmunityBio (IBRX) rests on Anktiva revenue ramp: Net product revenue grew roughly 700% in full-year 2025 to about ~$113M, and Q1 2026 revenue rose about 168% year over year to roughly ~$44M. Revenue (FY2025) is ~$113M net product revenue. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: IBRX carries the full risk profile of an unprofitable commercial-stage biotech. Whether IBRX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy. Its lead approved use is in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and the company is pushing label expansions into BCG-naive bladder cancer and lung cancer while building out global commercial partnerships across roughly 33 to 34 countries. The founder and largest shareholder, Patrick Soon-Shiong, remains central to the story and its strategy. The investment picture is a classic early-commercial biotech: revenue is growing very quickly but from a small base, the company is still deeply unprofitable, and it burns cash each quarter, which has historically been funded through equity and financing that dilutes existing holders. As of JULY 2026 the market value (roughly ~$8.7B) is large relative to trailing revenue (~$113M for full-year 2025), so the price embeds substantial expectations for future label expansions and adoption. That combination of approved-product traction plus a big valuation on small sales makes IBRX a high-variance name whose outcome hinges on execution, regulatory decisions, and access to capital.
What's the case for buying IBRX?
1. Anktiva revenue ramp
Net product revenue grew roughly 700% in full-year 2025 to about ~$113M, and Q1 2026 revenue rose about 168% year over year to roughly ~$44M. Continued physician uptake in BCG-unresponsive NMIBC is the core near-term growth engine. The base is still small, so percentage growth can stay high while absolute dollars remain modest.
2. Label and indication expansion
ImmunityBio is pursuing expansion into BCG-naive NMIBC, with a pivotal trial reported as fully enrolled and an sBLA submission targeted for 2026, plus early data in lung cancer. Each additional approved use widens the addressable population. These expansions are also the main justification for the current valuation, so timing and outcomes matter a great deal.
3. Global commercial partnerships
The company has signed distribution and approval arrangements spanning roughly 33 to 34 countries across multiple regulatory jurisdictions. International approvals can add revenue without ImmunityBio bearing the full commercial cost. Execution across many geographies and partners adds complexity and uncertainty.
4. Broader immunotherapy pipeline
Beyond Anktiva monotherapy combinations, ImmunityBio is exploring NK-cell therapy and other immunotherapy combinations across solid tumors. A wider pipeline offers optionality if additional programs advance. Most of these remain early and unproven, so they are potential upside rather than current value.
What are the risks to IBRX?
IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses (a Q1 2026 net loss of roughly ~$633M versus about ~$130M a year earlier, inflated by non-cash items, with an adjusted net loss near ~$86M) and burns roughly ~$75M of operating cash per quarter, which repeatedly requires financing that can dilute existing shareholders. Its market value (about ~$8.7B) is very large relative to trailing revenue (~$113M), so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks.
How is IBRX valued? (as of JULY 2026)
Snapshot for IBRX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$113M net product revenue
- Revenue growth (Q1 2026 YoY): ~168%
- Q1 2026 net product revenue: ~$44M
- Cash and marketable securities (Mar 31, 2026): ~$381M
- Quarterly operating cash burn: ~$75M
- Market capitalization: ~$8.7B
The valuation is striking: a multi-billion-dollar market value against roughly ~$113M of trailing revenue implies a very high price-to-sales multiple and prices in significant future growth. The company is not profitable and funds ongoing losses partly through financing, so cash runway and dilution are central to the story. These figures are as of JULY 2026 and shift with each quarterly report and any capital raise.
How do you decide if IBRX is a buy?
Rather than asking whether IBRX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold IBRX indirectly through an index or sector ETF before adding more.
For the full picture, see the IBRX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IBRX against your real portfolio and see your actual exposure before deciding.
The bottom line on IBRX
The bottom line: ImmunityBio's story right now is Anktiva revenue ramp, with revenue (fy2025) at ~$113M net product revenue. If you believe that narrative continues, the call is about sizing IBRX sensibly and checking overlap with what you own; if you doubt it (the risk: iBRX carries the full risk profile of an unprofitable commercial-stage biotech.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around IBRX with Walnut
Use ImmunityBio as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is IBRX a good stock to buy right now?
+
The case for ImmunityBio right now is Anktiva revenue ramp, with revenue (fy2025) at ~$113M net product revenue. If you believe that thesis holds, IBRX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is iBRX carries the full risk profile of an unprofitable commercial-stage biotech. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does ImmunityBio do?
+
ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy.
What are the main risks of IBRX?
+
IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses (a Q1 2026 net loss of roughly ~$633M versus about ~$130M a year earlier, inflated by non-cash items, with an adjusted net loss near ~$86M) and burns roughly ~$75M of operating cash per quarter, which repeatedly requires financing that can dilute existing shareholders. Its market value (about ~$8.7B) is very large relative to trailing revenue (~$113M), so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks.
What does ImmunityBio (IBRX) do?
+
ImmunityBio is a commercial-stage immunotherapy company. Its lead product, Anktiva, is an FDA-approved IL-15 receptor agonist immunotherapy used with BCG for BCG-unresponsive non-muscle invasive bladder cancer, and the company is pursuing additional cancer indications.
Is IBRX profitable?
+
No. As of JULY 2026 ImmunityBio is unprofitable and reports large net losses while it invests in commercialization and trials. It burns roughly ~$75M of operating cash per quarter, which it has funded partly through financing that can dilute shareholders.
How fast is Anktiva revenue growing?
+
Very fast off a small base. Full-year 2025 net product revenue rose about 700% to roughly ~$113M, and Q1 2026 revenue grew about 168% year over year to roughly ~$44M. High percentage growth reflects the early stage of the launch.
Why is IBRX's market cap so large versus its revenue?
+
The market value (about ~$8.7B as of JULY 2026) is large relative to trailing revenue (~$113M), which implies a very high price-to-sales multiple. That reflects investor expectations for future label expansions and adoption rather than current earnings.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell IBRX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.